News & Updates

First-line osimertinib plus chemotherapy further extends PFS in advanced EGFR-mutated NSCLC

The third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib, is preferred over earlier-generation EGFR TKIs as the first-line agent in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). In an interview with MIMS Oncology, Dr James Ho, Specialist in Respiratory Medicine in Hong Kong, discussed the positive survival outcomes associated with first-line treatment with osimertinib plus chemotherapy together in patients with advanced EGFR-mutated NSCLC, and shared which patients may benefit from this upfront combination treatment strategy.

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

At the Asia Vaccines and Antivirals Summit (AVAS) 2025 held in Bangkok, Thailand, two expert-led sessions provided valuable perspectives on the expanding role of oral antivirals in COVID-19 management. Dr Daniel Griffin, an infectious disease specialist and Clinical Instructor of Medicine at Columbia University, New York, US, focused on protecting high-risk populations through the timely use of antiviral therapy. Complementing this, Professor Ching-Tai Huang of Chang Gung University and Memorial Hospital in Taiwan offered practical guidance on clinical management strategies, including patient risk stratification and therapeutic selection.

Cough variant asthma: A diagnostic challenge with a simple solution

Multiple antibiotic exposures in early life may have long-term respiratory consequences

Preterm infants with multiple episodes of antibiotic exposure prenatally have a higher likelihood of having impaired lung function at early school age, as shown in a study.

Cardiac events common among individuals hospitalized for RSV infection

One in 10 individuals hospitalized for a respiratory syncytial virus (RSV) infection has a concurrent acute cardiovascular event, and this number is higher than that observed among individuals hospitalized for a COVID-19 infection, according to a study from Singapore.

COPD detection refined with new diagnostic schema

Incorporating spirometry with respiratory symptoms and quality of life and structural lung abnormalities on CT imaging to meet criteria for a chronic obstructive pulmonary disease (COPD) diagnosis spots additional patients at risk of poor respiratory outcomes, according to the results of a study presented at the ATS annual meeting and simultaneously published in JAMA.

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

Cytisinicline’s efficacy and tolerability for smoking cessation has been validated in another large phase III trial conducted in the US, with both the 6- and 12-week treatments yielding positive benefits persisting through 24 weeks.